Mark E. Bunnage
Evp, Chief Scientific Officer at Vertex Pharmaceuticals Inc / Ma (VRTX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $3.0M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| May 19SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 33 | $453.45 | $15K | +11.0% |
| Feb 26SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 620 | $486.35 | $302K | +3.5% |
| Feb 19SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 2,437 | $489.46 | $1.2M | +2.9% |
| Feb 19SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 1,182 | $473.68 | $560K | +6.3% |
| Feb 12SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 2,021 | $460.43 | $931K | +9.4% |
- Sell
Evp, Chief Scientific Officer Mark E. Bunnage sold $15K of VRTX at $453.45 — pre-scheduled 10b5-1 plan sale.
- Sell
Evp, Chief Scientific Officer Mark E. Bunnage sold $302K of VRTX at $486.35 — pre-scheduled 10b5-1 plan sale.
- Sell
Evp, Chief Scientific Officer Mark E. Bunnage sold $1.2M of VRTX at $489.46 — pre-scheduled 10b5-1 plan sale.
- Sell
Evp, Chief Scientific Officer Mark E. Bunnage sold $560K of VRTX at $473.68 — pre-scheduled 10b5-1 plan sale.
- Sell
Evp, Chief Scientific Officer Mark E. Bunnage sold $931K of VRTX at $460.43 — pre-scheduled 10b5-1 plan sale.